Immix Biopharma, Inc. (IMMX)
NasdaqCM · USD · Healthcare · Biotechnology
$8.06 (-1.10%) as of
Key statistics
- Market cap
- 668.20M
- Forward P/E
- -8.51
- EPS (TTM)
- -0.88
- Dividend yield
- 0.00%
- 52-week range
- 2.85 – 15.10
- Beta
- 0.24
- Profit margin
- 0.00%
- Analyst target
- $24.43
- Volume
- 1.12M
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Los Angeles, CA, United States
- Employees
- 21
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.